


PHARMACEUTICAL 2019

Regulus Therapeutics Inc. Rank 318 of 371







PHARMACEUTICAL 2019



Regulus Therapeutics Inc. Rank 318 of 371

The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 131% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 295% points.

The company's Economic Capital Ratio, given in the ranking table, is -662%, being 330% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	19,295
Cost of Goods Sold	0
Intangible Assets	500
Liabilities, Current	26,646
Liabilities, Non-Current	315
Other Assets	326
Other Compr. Net Income	0
Other Expenses	2,405
Other Liabilities	6,820
Other Net Income	0
Property and Equipment	7,806
Research and Development	33,975
Revenues	531
Selling, General and Administrative Expense	12,860

Output Variable	Value in 1000 USD
Assets	27,927
Liabilities	33,781
Expenses	49,240
Stockholders Equity	-5,854
Net Income	-48,709
Comprehensive Net Income	-48,709
Economic Capital Ratio	-662%